Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 122

Drug Profile

AB 122

Alternative Names: AB-122; GLS-010; WBP-3055

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WuXi Biologics
  • Developer Arcus Biosciences; Beijing Cancer Hospital; Guangzhou Gloria Biosciences; Harbin Gloria Pharmaceuticals; Strata Oncology; WuXi Biologics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical cancer; Hodgkin's disease
  • Phase I Breast cancer; Cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Nov 2019 Arcus Biosciences plans a phase II trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) in early 2020
  • 21 Oct 2019 Phase-I clinical trials in Pancreatic cancer (Late-stage disease, Combination therapy, Metastatic disease, First-line therapy) in USA (IV) (NCT04104672)
  • 11 Oct 2019 Arcus Biosciences plans a phase I trial for Pancreatic Cancer (Late stage disease, Combination therapy, Metastatic disease) in October 2019 (NCT04104672)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top